WS Investor
20 Apr 2026, 15:48
AstraZeneca's Tozorakimab Scores Third Positive Phase III Trial in COPD
AstraZeneca has reported positive results from the Phase III MIRANDA trial of tozorakimab, its experimental IL-33-targeting biologic for chronic obstructive pulmonary disease (COPD). The drug met its primary endpoint, delivering a statistically significant and clinically meaningful reduction in moderate-to-severe COPD exacerbations — both in former smokers and in the broader trial population including current smokers, across all stages of lung function severity.
MIRANDA is the third consecutive positive pivotal trial for tozorakimab in COPD, following the OBERON and TITANIA results announced in March. The drug works by blocking IL-33 signalling in two distinct ways, targeting both inflammation and the mucus dysfunction cycle that drives disease worsening. It was generally well tolerated with a safety profile consistent with earlier studies.
The results are significant given the scale of unmet need: COPD affects nearly 400 million people worldwide and is the third leading cause of death globally, yet more than half of patients continue to suffer exacerbations even on standard inhaled therapies. AstraZeneca said it will submit the data to regulatory authorities and present findings at an upcoming medical conference.
AstraZeneca has reported positive results from the Phase III MIRANDA trial of tozorakimab, its experimental IL-33-targeting biologic for chronic obstructive pulmonary disease (COPD). The drug met its primary endpoint, delivering a statistically significant and clinically meaningful reduction in moderate-to-severe COPD exacerbations — both in former smokers and in the broader trial population including current smokers, across all stages of lung function severity.
MIRANDA is the third consecutive positive pivotal trial for tozorakimab in COPD, following the OBERON and TITANIA results announced in March. The drug works by blocking IL-33 signalling in two distinct ways, targeting both inflammation and the mucus dysfunction cycle that drives disease worsening. It was generally well tolerated with a safety profile consistent with earlier studies.
The results are significant given the scale of unmet need: COPD affects nearly 400 million people worldwide and is the third leading cause of death globally, yet more than half of patients continue to suffer exacerbations even on standard inhaled therapies. AstraZeneca said it will submit the data to regulatory authorities and present findings at an upcoming medical conference.